2025
SJR Q1
JCR Q1 · 7,4
5 matched articles
SCIE
Journal detail
Diabetes Technology and Therapeutics
- Publisher
- Mary Ann Liebert Inc.
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
1520915615578593
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 2,663
- Quartile Q1
- H-Index 116
- Cites/doc 6,68
- Docs (3y) 432
- Cites (3y) 2.681
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 7,4
- 5Y JIF 5,8
- JCI 1,66
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Endocrinology Q1
- Endocrinology, Diabetes and Metabolism Q1
- Medical Laboratory Technology Q1
- Medicine (miscellaneous) Q1
Areas
- Biochemistry, Genetics and Molecular Biology
- Health Professions
- Medicine
WoS categories
- Endocrinology & Metabolism
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 2,663 | 7,4 | 5,8 | 1,66 | Q1 | 116 |
| 2024 | Q1 | Q1 | 3,609 | 6,3 | 5,9 | 1,57 | Q1 | 109 |
| 2023 | Q1 | Q1 | 2,957 | 5,7 | 6,7 | 1,39 | Q1 | 109 |
| 2022 | Q1 | Q1 | 2,374 | 5,4 | 5,6 | 1,45 | Q1 | 109 |
| 2021 | Q1 | Q1 | 2,66 | 7,3 | 5,7 | 1,37 | Q1 | 109 |
| 2020 | Q1 | Q1 | 2,142 | 6,1 | 4,7 | 1,28 | Q1 | 109 |
| 2019 | Q1 | Q1 | 1,819 | 4,4 | 3,5 | 1,11 | Q1 | 109 |
| 2018 | — | Q1 | — | 4,5 | 3,5 | 1,03 | Q1 | — |
| 2017 | Q1 | Q3 | 1,735 | 2,9 | 2,7 | 0,76 | Q2 | 109 |
| 2016 | Q1 | Q3 | 1,361 | 2,7 | 2,6 | — | — | 109 |
| 2015 | Q1 | Q3 | 1,245 | 2,2 | 2,2 | — | — | 109 |
| 2014 | Q1 | Q3 | 1,332 | 2,1 | 2,1 | — | — | 109 |
| 2013 | Q1 | Q3 | 1,179 | 2,3 | 2,2 | — | — | 109 |
| 2012 | Q1 | Q3 | 1,007 | 2,2 | 2,2 | — | — | 109 |
| 2011 | Q1 | Q3 | 1,061 | 1,9 | 2 | — | — | 109 |
| 2010 | Q1 | Q3 | 1,071 | 2,1 | — | — | — | 109 |
| 2009 | — | Q3 | — | 2,6 | — | — | — | — |
| 2008 | — | Q3 | — | 2,1 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ENDOCRINOLOGY & METABOLISM | SCIE | Q1 | Q1 | 21/198 |
| 2024 | ENDOCRINOLOGY & METABOLISM | SCIE | Q1 | Q1 | 24/193 |
| 2023 | ENDOCRINOLOGY & METABOLISM | SCIE | Q1 | Q1 | 25/186 |
| 2022 | ENDOCRINOLOGY & METABOLISM | SCIE | Q1 | Q1 | 34/145 |
| 2021 | ENDOCRINOLOGY & METABOLISM | SCIE | Q1 | Q1 | 25/146 |
| 2020 | ENDOCRINOLOGY & METABOLISM | SCIE | Q1 | Q1 | 25/146 |
| 2019 | ENDOCRINOLOGY & METABOLISM | SCIE | Q1 | Q1 | 30/143 |
| 2018 | ENDOCRINOLOGY & METABOLISM | SCIE | Q1 | Q1 | 30/145 |
| 2017 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | Q2 | 79/142 |
| 2016 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 76/138 |
| 2015 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 91/133 |
| 2014 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 87/128 |
| 2013 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 74/124 |
| 2012 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 75/122 |
| 2011 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 83/122 |
| 2010 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 79/116 |
| 2009 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 54/105 |
| 2008 | ENDOCRINOLOGY & METABOLISM | SCIE | Q3 | — | 63/93 |